William Sheridan

BioCryst Pharmaceuticals (United States) — United States

Medicine · Health Sciences

37h-index6.9kcitations146works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Coagulation, Bradykinin, Polyphosphates, and Angioedema(30), Neutropenia and Cancer Infections(22), Hematopoietic Stem Cell Transplantation(15), Platelet Disorders and Treatments(15), Blood groups and transfusion(13)

Publications145 total

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Complement Factor D Inhibitor BCX9930 in Healthy Participants
The Journal of Clinical Pharmacology·2025Open Access
CyberKnife Treatment of Medically Intractable Trigeminal Neuralgia: A Comparison of Isocentric and Non-isocentric Treatment Planning Outcomes
Cureus·2025· 1 citedOpen Access
The efficacy of <scp>GLP‐1RAs</scp> for the management of postprandial hypoglycemia following bariatric surgery: a systematic review
Obesity·2022· 37 citedOpen Access
P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS
HemaSphere·2022· 4 citedOpen Access
POS-045 Evaluating BCX9930, an Oral Factor D Inhibitor for Treatment of Complement-Mediated Kidney Disease: A Proof-of-Concept Study (RENEW)
Kidney International Reports·2022· 6 citedOpen Access
P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
HemaSphere·2022· 6 citedOpen Access
POS-041 BCX9930, AN ORAL FACTOR D INHIBITOR, SUPPRESSES COMPLEMENT ALTERNATIVE PATHWAY ACTIVITY IN PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY
Kidney International Reports·2022Open Access
Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema
Clinical and Translational Science·2022· 5 citedOpen Access
Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects
Clinical Pharmacology in Drug Development·2022· 14 citedOpen Access
P053 SUSTAINED REDUCTION IN HEREDITARY ANGIOEDEMA ATTACK RATES FOLLOWING SWITCH TO BEROTRALSTAT: SUBGROUP ANALYSIS FROM APEX-2
Annals of Allergy Asthma & Immunology·2021· 1 cited
D005 CONSISTENTLY LOW HEREDITARY ANGIOEDEMA (HAE) ATTACK RATES OBSERVED IN US PATIENTS TREATED WITH BEROTRALSTAT
Annals of Allergy Asthma & Immunology·2021
P045 BEROTRALSTAT DEMONSTRATES LOW HEREDITARY ANGIOEDEMA (HAE) ATTACK RATES IN PATIENTS SWITCHING FROM INJECTABLE PROPHYLAXIS
Annals of Allergy Asthma & Immunology·2021
Effects of glucagon‐like peptide‐1 receptor agonists on histopathological and secondary biomarkers of non‐alcoholic steatohepatitis: A systematic review and meta‐analysis
Diabetes Obesity and Metabolism·2021· 9 citedOpen Access
BCX9930, an Oral Factor D Inhibitor in Development for Treatment of Complement-Mediated Diseases, Inhibits Complement Alternative Pathway (AP) Activity in Healthy Subjects
Journal of the American Society of Nephrology·2021
Author response for "The effects of GLP ‐1 receptor agonists on histopathological and secondary biomarkers of non‐alcoholic steatohepatitis: A systematic review and meta‐analysis"
2021
Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
Clinical and Translational Allergy·2021· 50 citedOpen Access
Weight loss with bariatric surgery or behaviour modification and the impact on female obesity‐related urine incontinence: A comprehensive systematic review and meta‐analysis
Clinical Obesity·2021· 19 citedOpen Access
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
The Journal of Allergy and Clinical Immunology In Practice·2021· 59 citedOpen Access
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
Allergy·2020· 45 citedOpen Access
BCX9930, a Potent, Selective, Oral Factor D Inhibitor, Demonstrates Proof-of-Concept As Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Blood·2020· 4 cited
page 1 of 8Next →

Frequent Co-authors

George Morstyn(9), Sylvia Dobo(8), Phil Collis(8), Graham J. Lieschke(7), Jonathan Cebon(7), Dermot Maher(6), Emel Aygören‐Pürsün(6), Melanie Cornpropst(6), R. M. Fox(5), C. Glenn Begley(5), Y.S. Babu(5), Judith E. Layton(5), Marcus Maurer(5), Jeff Szer(4), Henriette Farkas(4), Jessica Best(4), Heather A. Iocca(4), Enikő Nagy(4), Sharon C. Murray(4), Jenna Elder(4)